$PFE

Three dividend stocks—Philip Morris, Pfizer, and UnitedHealth—offer compelling long-term value despite significant recent declines, supported by healthcare demographics and business transformation.

Trump administration preparing 100% tariffs on pharmaceutical companies refusing pricing deals, with major drugmakers already securing three-year reprieves through MFN agreements.

Esophageal cancer market projected to grow 44% to $2.37B by 2030 at 9.5% CAGR, with Pfizer, Roche, and Merck dominating through precision oncology and immunotherapy innovations.

Pfizer pursues GLP-1 market opportunity through acquisition after internal failure, offering 6.2% dividend yield amid 50% stock decline from 2021 peaks.

Viking Therapeutics' VK2735 could threaten Novo Nordisk and Eli Lilly's GLP-1 dominance if phase 3 trials succeed, triggering potential threefold gains or severe losses.

$LLY dominates GLP-1 market with strong Mounjaro, Zepbound sales but trades at 40x P/E—well above pharma peers—raising concerns about priced-in perfection.

Valneva stock plummets 37% after Phase 3 Lyme vaccine candidate fails trial; law firm investigates potential securities fraud claims.

Clinical-stage biotech Serina Therapeutics will present at 38th Annual Roth Conference on March 24, 2026, highlighting its proprietary POZ Platform technology and pipeline.

Valneva-Pfizer Lyme vaccine trial misses primary endpoint but shows 73-75% secondary efficacy; Pfizer to seek regulatory approval despite setback. Valneva shares fell 35.27%.

Pfizer and UnitedHealth Group present buying opportunities for $500 investors. Pfizer trades at 9x forward earnings with oncology growth plans; UnitedHealth at 15x after cost-cutting initiatives.

Anaveon appoints veteran biotech executive Thaminda Ramanayake as CEO to guide lead candidate ANV200 through clinical development for autoimmune and inflammatory diseases.

Eli Lilly dominates weight management, Vertex controls cystic fibrosis, and Pfizer offers undervalued shares with 6.3% dividend yield.

Healthcare sector faces pullback amid Middle East tensions, but dividend-paying stocks and funds offer yields of 6-14.1% with varying risk profiles.

Moderna's 69% YTD gain reflects mRNA vaccine upside, while Pfizer's 6.3% dividend offers stability as COVID revenues fade. Choice depends on risk appetite.

Pfizer shares rise on Phase 3 prostate cancer trial win and Phase 2 breast cancer success, validating its oncology pipeline and signaling near-term regulatory catalysts.

Eli Lilly's GLP-1 drugs drive 56% of revenues with explosive growth, but 43x P/E valuation leaves no room for disappointment amid intensifying competition and future patent risks.

Three healthcare stocks under $50 offer distinct value: Pfizer at $27.45 with 9x P/E and strong oncology pipeline; Novo Nordisk at $38.43 capitalizing on weight-loss drugs; Exelixis at $41.80 with proven oncology franchise.

Pfizer reports positive Phase 2 data for atirmociclib in metastatic breast cancer, meeting survival endpoints. Company also gains FDA approval for Braftovi in colorectal cancer.

Pfizer faces patent cliffs and COVID vaccine decline, betting on oncology and obesity drug pipelines to drive future growth amid acquisition integration challenges.

Amgen and GSK join TrumpRx.gov offering up to 80% and 10-55% discounts respectively, expanding the platform to 54 drugs amid Trump administration pricing pressure.